Founded in 2016 and focused on a core mission of realizing a world with 'an effective treatment option for every patient,' CAMP4 Therapeutics evolved from seminal discoveries made by company founders Dr. Richard Young and Dr. Leonard Zon, characterizing the ways in which dynamic cell signaling networks control the expression of genes. Operating at the intersection of genomics, computational biology and data sciences, CAMP4 has extended this foundational work, creating a unique Gene Circuitry Platform to amplify the value of cellular and genetic insights to better understand how genes are controlled by signaling pathways in specific disease states. By generating proprietary 4D maps, CAMP4 can identify de-risked druggable targets, produce actionable insights and improve therapeutic predictability, potentially addressing hundreds of diseases and benefiting millions of patients globally.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/31/18 | $30,000,000 | Series A |
Polaris Partners The Kraft Group | undisclosed |
